This is a repository copy of Response to: 'Comparing the immunogenicity of the etanercept biosimilar SB4 with the innovator etanercept: another consideration' by Marshall et al..

White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/98300/

Version: Accepted Version

Article:

https://doi.org/10.1136/annrheumdis-2016-209517

This is an author produced version of a paper published in Annals of the Rheumatic Diseases. Uploaded in accordance with the publisher's self-archiving policy.

Reuse
Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website.

Takedown
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
Response to the ‘comparing the immunogenicity of the etanercept biosimilar SB4 with the innovator etanercept: another consideration’ by Marshall et al.

Correspondence to Professor Paul Emery, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Chapeltown Road, Leeds, LS7 4SA, UK; p.emery@leeds.ac.uk

Paul Emery1,2, Jiří Vencovský3, Jeehoon Ghil4, Jung Won Kang5
1 Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, UK
2 NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK
3 Institute of Rheumatology, Prague, Czech Republic
4 Samsung Bioepis Co., Ltd. Incheon, Republic of Korea

We thank Marshall et al for the interest in and comments on our SB4 Phase III study publication and subsequent correspondence regarding immunogenicity.[1-3]

Anti-drug antibody (ADA) incidence in clinical trials varies widely, and is dependent on both the ADA assay method and sampling schedule. In the SB4 Phase III study[1], the MSD electrochemiluminescence (ECL) bridging assay (Meso Scale Discovery, MD, USA) with acid dissociation which is considered to be a sensitive assay was used. ADAs and neutralising antibodies (NAbs) were measured earlier and more frequently in our study (weeks 0, 2, 4, 8, 12, 16, 24, and 52) than previous studies with etanercept reference product (ETN). Most of the ADAs in the ETN treatment group were detected at weeks 4-8 when ADAs were not usually measured in the previous studies with ETN [4-10], partially accounting for the apparent discrepancy of ADA incidence between this study and the previously published clinical studies. In addition, advances in assay technology over time could contribute to the higher ADA incidence [1 11-16] (in RA patients approximately 6%[17] vs. 13%[1] for etanercept, 8%[18] vs. 48%[13] for infliximab, and 5.5%[19] vs. 38%[20] for adalimumab in historical studies vs. recent biosimilar studies, respectively).

We reported significantly lower incidence of ADA in SB4 (0.7%) compared to ETN (13.1%) up to week 24 (p<0.001).[1] The CHMP conclusion about SB4 was that “the favourable immunogenicity profile of SB4 compared to ETN was uncertain because of the low drug tolerance of the ADA assay
that led to a low sensitivity and a potential bias”.[21] In regards to inconsistent conclusion between EPAR and this publication, we would like to point out the following.

As the presence of the drug could have increased false negative ADA results in SB4 and ETN, immunogenicity was re-assessed using the improved assay in terms of drug interference[22] in a subset of patients whose serum drug concentrations were measured (pharmacokinetic [PK] population; 41 patients in SB4 and 38 patients in ETN). This assay could detect 500 ng/mL anti-SB4 and anti-ETN antibodies in the presence of 10 μg/mL of etanercept. The serum concentrations of etanercept in our study ranged from 0 μg/mL to 6.356 μg/mL, and thus the amended ADA assay was more tolerable in detecting ADA in terms of drug interference. With the amended ADA assay, the incidence of ADA up to week 24 in the PK population was 2.4% (1/41) in SB4 treatment group and 21.1% (8/38) in the ETN treatment group (results to be published).

In the Phase I study with SB4[23], immunogenicity was measured 28 days after a single injection of etanercept when the serum concentration of etanercept (ranged from 0 ng/mL to 238.97 ng/mL) was far below the drug tolerance level of ADA assay used in MSD ECL assay, which could detect 500 ng/mL of anti-SB4 and anti-ETN antibodies in the presence of 2-3 μg/mL of etanercept, i.e. all ADAs were measured without any drug interference.[24] Consistent with the Phase III results, the ADA incidence was significantly lower in SB4 (0.0%, 0/45) compared to EU-ETN (15.6%, 7/45, p = 0.006 compared with SB4) or US-ETN (22.7%, 10/44, p < 0.001 compared with SB4).[23]

We hope that the above additional information allow the readers of the Annals of the Rheumatic Diseases to make well-informed decisions, and to be re-assured that the immunogenicity data in our publication is valid and reliable.
References:
demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab
when coadministered with methotrexate in patients with active rheumatoid arthritis: the
14. Kay J LC, Trokan L. Safety Profile of BOW015, A Biosimilar Infliximab, In Healthy Subjects and
Antibody Status of ABP 501, A Biosimilar Candidate to Adalimumab. 2015;74:Suppl 2 714
comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients
17. Enbrel Summary of Product Characteristics.
Safety of ABP 501 Compared with Adalimumab in Subjects with Moderate to Severe Rheumatoid
Arthritis Arthritis Rheumatol 2015;67 (suppl 10).
neutralizing antibody, residual drug, and human immunoglobulin G in immunogenicity assay
24. Chen DY, Chen YM, Tsai WC, et al. Significant associations of antidrug antibody levels with
serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in